Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Islets of Langerhans Stories

2013-05-07 11:05:38

Some of the earliest results from The Environmental Determinants of Diabetes in The Young (TEDDY) study - a major Europe-USA consortium exploring the causes of type 1 diabetes in children — has found no evidence for viral infection as a cause of the rapid-onset form of the condition. The research appears in Diabetologia, the journal of the European Association for the Study of Diabetes (EASD) and is by Professor Anette-Gabriele Ziegler of the German Research Centre for Environmental...

Mouse Model Sheds New Light On How Diabetes Develops
2013-05-04 06:20:44

redOrbit Staff & Wire Reports - Your Universe Online A team of Swedish scientists has developed a new mouse model which could explain what exactly happens to the body when type 2 diabetes develops, as well as how drug treatment affects the physiology. Writing in the journal Diabetologia, researchers from Lund University explain they fed normal mice food that was high in fat from the age of eight months through the age of two (which is, on average, the end of their natural lives)....

2013-03-05 08:30:29

New platform mimics native pancreas, contains real cells to normalize blood sugar in real time MIAMI, Fla., March 5, 2013 /PRNewswire-USNewswire/ -- Scientists from the Diabetes Research Institute (DRI) at the University of Miami are taking a quantum leap toward a biological cure for diabetes by unveiling the DRI BioHub, a bioengineered "mini organ" that contains lifesaving insulin-producing cells that can sense blood sugar and release the precise amount of insulin needed in real time....

2013-02-28 10:56:12

The origin of beta-cells, the insulin-producing cells in the islets of Langerhans in the pancreas, has been controversial, and now new imaging and cell analysis technology shows that a recent study that seemed to have identified the progenitors of these important cells may have been in error, said researchers from Baylor College of Medicine, Texas Children´s Hospital and the University of Pennsylvania School of Medicine in Philadelphia. "This is a fundamental question for my field,"...

2013-01-08 12:23:26

NEW YORK, Jan. 8, 2013 /PRNewswire/ -- Islet Sciences, Inc., (OTC Bulletin Board: ISLT) a clinical stage company engaged in the research, development and commercialization of therapeutics in the field of diabetes, announced today that it was included in the December 27, 2012 issue of BioWorld Today. A link to the full text of the article is below. "Inclusion in BioWorld is another validation point as this esteemed industry publication recognizes the potential of Islet Sciences," stated...

2012-10-11 15:23:58

NEW YORK, Oct. 11, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced the publishing of results from a study regarding the production and function of IL-12 in Islets and Beta cells. The conclusion and interpretation of the study is that these data identify beta cells as a local source of IL-12...

2012-09-12 06:31:25

NEW YORK, Sept. 12, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that it has exclusively licensed technology from the University of California to commercialize an invention for expanding pancreatic islets. "In the course of research conducted at the University of California, Los Angeles,...

2012-09-10 02:29:24

NEW YORK, Sept. 10, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that it has exclusively licensed technology from Winthrop University Hospital. This technology is complimentary to the early Beta cell destruction diagnostic that Islet Sciences licensed last month. "In the course of research...

2012-09-06 02:32:18

NEW YORK, Sept. 6, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced the following additions to its Scientific Advisory Board: Dr. Kevan Herold and Dr. Morton Printz. "These key additions to our Scientific Advisory Board are demonstrative of our progress, and the leading edge therapies for...

2012-09-04 06:28:30

NEW YORK, Sept. 4, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that the company has named Richard A. Franco, Sr. to its Board of Directors. Richard A. Franco is the President of the Richard's Group, Ltd., a healthcare advisory firm and cofounder of LipoScience, Inc. He has over 35 years...